Skip to main content
Equibles
NXL logo

NXL · Nexalin Technology, Inc.

Track NXL — free

Use NXL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.25 0.00 (-1.88%) At close · Aug 28
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has evaluated these conditions and concluded that the Company does not currently have sufficient cash and cash equivalents to fund its anticipated operating requirements for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. Accordingly, substantial doubt exists about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$183,636
Shares
734,547

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.25 Open$0.26 Day$0.25–0.26 52W close$0.25–1.86 Avg vol 30d198K Short int11K · 1.6% float · 3.0d Short vol41% DataSep 2022–Aug 2026 Filing10-Q · Aug 12

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 12, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −53%
below
Price vs 50-day avg −33%
below
RSI (14) 27
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −26%
trailing
6-month return −45%
trailing
YTD return −55%
this year
Relative strength −58%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-13% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.55% of float · ▲ +5.8% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
20 holders — mid 3-yr range
Squeeze score 49
elevated · 0–100
Fundamentals
Excellent
Revenue growth +79%
Y/Y
Gross margin 80%
expanding
EPS growth +40%
Y/Y
Quant / Vol
risk profile
Very High
Volatility 144%
annualized · 1-yr
Max drawdown −87%
past year
ATR 12.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−53% Bearish
Price vs 50-day avg
−33% Bearish
RSI (14)
27 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-13% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.55% of float · ▲ +5.8% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
20 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $2
vs 200-day avg -53% vs 50-day avg -33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NXL
Nexalin Technology, Inc.
this stock
$183,636 -55.2% +78.8% — 1.6%
ABT
Abbott Laboratories
 $195.90B -10.2% +5.7% 31.5 1.2%
SYK
Stryker Corp
 $127.12B -5.9% +11.2% 34.3 1.8%
MDT
Medtronic plc
 $116.78B -5.0% +8.4% 24.5 1.1%
BSX
Boston Scientific Corp
 $67.88B -50.9% +12.5% 19.0 1.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
20
% held
3.9%
Net QoQ
-7.2K sh
Top holder
PEAK6 LLC
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Rising
Shares short
11.4K
Days to cover
3.0d
Change
+628 sh
View
Short Volume
Short vol %
41%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
796
Value
$271
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
61.5%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$301.6K
Net income (FY)
$-8.2M
EPS diluted
$-15.00
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 27, 2026
This year
16
View
Proposed Sales
Value
$403
Shares
23.2K
Filed
Sep 10, 2025
View

Performance

5D 20D 120D MTD YTD
NXL -24.7% -26.0% -45.1% -26.0% -55.2%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -25.2% -29.0% -58.5% -29.0% -68.0%
Key facts CIK 1527352 CUSIP 65345B201 13F (30d) 19 filings 19 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)